Search for
Drug of Abuse-Cannabinoids By Rapid
Blood
Report in 4Hrs
At Home
No Fasting Required
Details
Rapid urine/blood screening panels.
₹222₹317
30% OFF
Drug of Abuse-Cannabinoids By Rapid Test Information Guide
- Why is it done?
- Detects the presence of cannabinoids (THC metabolites) in biological specimens to identify cannabis use
- Used for workplace drug screening programs to maintain a drug-free environment and ensure employee safety
- Employed in substance abuse treatment and rehabilitation programs for monitoring patient compliance
- Utilized in legal and forensic settings including DUI investigations and legal proceedings
- Employed in medical settings for patients on chronic pain management or those with substance use disorders
- Rapid immunoassay methodology provides quick results, typically within minutes, allowing immediate decision-making
- Commonly used during pre-employment screening, random testing, reasonable suspicion testing, and return-to-work evaluations
- Normal Range
- Reference Value: NEGATIVE (Cutoff level: typically 50 ng/mL for standard screening or 20 ng/mL for sensitive screening)
- Negative Result: No cannabinoids detected at or above the established cutoff threshold; indicates no recent cannabis use or concentration below detection limits
- Positive Result: Cannabinoids detected at or above the cutoff level; indicates recent cannabis use within typically 3-7 days for occasional users or up to 30 days for chronic users
- Units of Measurement: nanograms per milliliter (ng/mL) for urine specimens; varies based on specimen type (saliva, blood, hair)
- Interpretation Framework: This is a qualitative screening test providing a dichotomous outcome (positive or negative); not a quantitative measure of drug concentration or impairment level
- Interpretation
- Negative Result Interpretation: Indicates absence of detectable cannabinoids; does not definitively exclude cannabis use as detection windows vary and some metabolites may not be identified
- Positive Result Interpretation: Suggests recent cannabis use but does not indicate impairment level, frequency of use, or timing of consumption; confirmatory testing recommended for positive results
- Detection Window: Urine-based testing can detect THC metabolites for 3-7 days in occasional users, 7-21 days in regular users, and potentially 30+ days in heavy daily users; varies with individual metabolism and specimen type
- Factors Affecting Results: Individual metabolic rate, body fat percentage, frequency and amount of cannabis use, specimen type, dilution status, and medication use may affect test accuracy and detection windows
- False Positives: Rare but possible; may occur from passive smoke exposure, cross-reactivity with certain medications or supplements, or technical errors; confirmatory testing via Gas Chromatography-Mass Spectrometry (GC-MS) recommended
- False Negatives: May occur with very recent use (before metabolites form), use of synthetic cannabinoids not detected by standard assays, or specimen dilution below detection threshold
- Clinical Significance: Positive results require follow-up and interpretation based on clinical context, occupational requirements, and legal jurisdiction; does not establish current impairment or confirm active intoxication
- Associated Organs
- Primary Target Organ Systems: Central nervous system (brain and spinal cord), respiratory system (lungs when smoked), hepatic system (liver for metabolite processing)
- Conditions Associated with Cannabis Use: Cannabis use disorder, substance use disorder, psychiatric conditions including anxiety and psychotic disorders, cognitive impairment, respiratory disorders (if smoked), cardiovascular effects
- Neurological Effects: Cannabis affects cannabinoid receptors in the brain; chronic use associated with cognitive deficits, memory impairment, attention problems, and potential impacts on executive function and motivation
- Respiratory Complications: Chronic smoking associated with airway inflammation, bronchitis, cough, phlegm production, and potential long-term respiratory disease; inhalation injuries
- Psychiatric Associations: Cannabis use associated with increased risk of psychotic disorders, particularly in genetically predisposed individuals; anxiety, depression, and altered mood regulation may occur
- Cardiovascular Effects: Acute use may increase heart rate and blood pressure; associated with myocardial infarction risk within hours of use, particularly in susceptible populations
- Hepatic Metabolism: Liver extensively metabolizes THC via cytochrome P450 enzymes; chronic use may affect liver function in some individuals; important for drug-drug interactions
- Follow-up Tests
- Confirmatory Testing: Gas Chromatography-Mass Spectrometry (GC-MS) or Liquid Chromatography-Mass Spectrometry (LC-MS) to confirm positive screening results and differentiate cannabinoids from potential cross-reactants
- Specimen Testing by Type: Hair testing (detects use up to 90 days), saliva testing (more recent use), or blood testing for acute intoxication assessment if initial urine results are positive
- Comprehensive Substance Screening: Expanded drug panel testing including other controlled substances, prescription medications, and synthetic cannabinoids depending on clinical or occupational context
- Clinical Assessment Tests: Impairment evaluation, sobriety tests, cognitive function assessments, and psychiatric evaluation if positive results require clinical determination of impairment status
- Substance Abuse Treatment Monitoring: Repeat testing at regular intervals (weekly, bi-weekly, or monthly) during treatment programs to monitor abstinence and treatment compliance
- Workplace Follow-up: Return-to-duty testing, follow-up random testing, and mandatory participation in Employee Assistance Program (EAP) for positive workplace test results
- Medical Evaluation: Complete physical examination, liver function tests, pulmonary function tests, mental health screening, and neuropsychological assessment if chronic use is suspected
- Legal or Forensic Follow-up: Chain of custody procedures, independent laboratory retesting, legal consultation, or court-ordered substance abuse evaluation as appropriate
- Fasting Required?
- Fasting Requirement: NO - Fasting is NOT required for this rapid cannabinoid screening test
- Specimen Collection Requirements: Provide a urine specimen (typical specimen type); may include saliva or blood specimens depending on test protocol; at least 30-45 mL of urine recommended
- Specimen Validity Measures: Testing conducted under observed or supervised collection in many contexts to ensure specimen integrity; temperature and specific gravity verification performed
- Pre-Test Instructions: Patients may eat and drink normally prior to testing; no dietary restrictions necessary; arrive at collection site with normal bladder volume for adequate specimen provision
- Medications to Consider: Continue all prescribed medications unless otherwise directed; certain medications do NOT need to be withheld; inform collection staff of all medications being taken for proper documentation
- Specimen Dilution: Avoid excessive fluid intake immediately before specimen collection as this may dilute the sample and potentially affect test results; normal hydration is appropriate
- Age-Related Considerations: Test can be performed on individuals of all ages with appropriate documentation and consent; special considerations for minors requiring parental/guardian notification or consent depending on jurisdiction
How our test process works!
